Trials / Unknown
UnknownNCT01388075
Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The genetic factors associated with variability in CYP2C9 induction have not been elucidated. The hypothesis underlying this study is that following 7 days treatment with rifampicin, a known CYP450 inducer, the genetic variability in regulatory elements controlling CYP2C9 expression will be associated with the magnitude of change in INR response to warfarin and in CYP2C9-mediated warfarin metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampicin | oral, 450 mg/day , 7 days |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2018-06-01
- First posted
- 2011-07-06
- Last updated
- 2011-07-06
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01388075. Inclusion in this directory is not an endorsement.